In Vivo Tracking of USPIO Labeled MSC in the Heart

Inclusion Criteria: * Age between 30 and 80 years. * Signed informed consent. * Chronic stable ischemic heart disease * New York Heart Association (NYHA) class II-IV or Canadian Cardiovascular Society (CCS) class II-IV * Maximal tolerable angina and/or heart failure medication. * Angiography within 12 months of inclusion. Angiography must have at least one larger coronary vessel with a significant stenosis with no option for revascularization (Angiographies evaluated by an independent thoracic surgeon and an interventional cardiologist). * Patients who have had revascularization done within 6 months of inclusion must have a new angiography at least 4 months after the intervention to rule out early restenosis. Exclusion Criteria: * Pregnant or fertile women. * Clinical significant anemia, leukopenia, leukocytosis or thrombocythemia. * Diminished functional capacity for other reasons such as: chronic obstructive pulmonary disease (COLD) with Forced Expiratory Volume in 1 second (FEV1)\<1 L/min, moderate to severe claudication or morbid obesity. * Patients with reduced immune response or treated with immunosuppressive medication. * Moderate to severe valvular disease or valvular disease with option for valvular surgery. * Acute coronary syndrome with elevation of coronary markers, stroke or Transitory Cerebral Ischemia (TCI) within 6 weeks of inclusion. * History with malignant disease within 5 years of inclusion or suspected malignity. * Other experimental treatment within 4 weeks of baseline evaluation. * Other revascularization treatment within 4 months of treatment. * Contraindications for Magnetic Resonance Imaging (MRI) such as: Claustrophobia, pacemaker, Implantable Cardioverter Defibrillator (ICD) unit, metal fragments or metal implants in the cranium